An ascending multiple dose study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SAM-531 administered orally to healthy young and elderly subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 10 Dec 2007 Status change from recruiting to completed.
- 31 Jul 2007 New trial record.